Effect of Academic Detailing on Promoting Appropriate Prescribing of Antipsychotic Medication in Nursing Homes: A Cluster Randomized Clinical Trial

Mina Tadrous, Kinwah Fung, Laura Desveaux, Tara Gomes, Monica Taljaard, Jeremy M Grimshaw, Chaim M Bell, Noah M Ivers, Mina Tadrous, Kinwah Fung, Laura Desveaux, Tara Gomes, Monica Taljaard, Jeremy M Grimshaw, Chaim M Bell, Noah M Ivers

Abstract

Importance: Strategies to reduce the inappropriate prescription of antipsychotics have been the focus of recent attention but have shown considerable variation in their effectiveness.

Objective: To evaluate the effectiveness of academic detailing in nursing homes targeting appropriate prescribing of antipsychotics.

Design, setting, and participants: We conducted a pragmatic, cluster randomized clinical trial comparing the effect of academic detailing vs usual care on prescribing antipsychotics in 40 nursing homes with 5363 residents in Ontario, Canada. Data were collected from October 2015 to March 2016 and analyzed from April to August 2018. Primary analyses were conducted using intention to treat.

Intervention: Academic detailing delivered by health professionals (eg, nurses or pharmacists) who arranged meetings (with administrators, physicians, pharmacists, nurses, and support workers), presentations, group visits (with 2-6 clinicians), and 1-on-1 visits (traditional academic detailing visits). Academic detailers had direct and ongoing contact with the nursing homes from the time of launch.

Main outcomes and measures: The primary outcome, defined at the level of the resident, was whether continuous antipsychotics were dispensed in the past week. Secondary outcomes included prescribing of other psychotropic medications and clinical outcomes and scores. Prescribing outcomes were assessed at baseline and at 3, 6, and 12 months, and clinical outcomes and scores were assessed at baseline and 3 and 6 months.

Results: A total of 40 nursing homes with 5363 residents were randomized, with 18 intervention homes (45.0%; 2303 [42.9%] residents) and 22 control homes (55.0%; 3060 [57.1%] residents). Participants in the intervention and control groups had similar median (interquartile range) age (86 [79-91] years vs 85 [78-90] years) and sex (674 [29.3%] men vs 970 [31.7%] men). At 12 months, there was no statistically significant difference in the frequency of daily antipsychotic use (intervention: 569 patients [25.2%]; control: 769 [25.6%]; odds ratio, 1.06; 95% CI, 0.93-1.20; P = .49). There were no significant differences in the rates of health care utilization, but the intervention group did experience a statistically significant reduction in pain compared with the control group (mean [SD] pain score, 0.30 [0.59] vs 0.38 [0.66]; P < .001) and depression (mean [SD] Depression Rating Scale score, 2.18 [2.37] vs 2.81 [2.65]; P < .001) at 6 months.

Conclusions and relevance: The intervention did not further reduce antipsychotic prescribing in nursing homes beyond system-level secular trends occurring alongside usual care. Our findings highlight the need for a more targeted approach to quality improvement strategies, including academic detailing, that account for the timing and topic of interventions.

Trial registration: ClinicalTrials.gov Identifier: NCT02604056.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Tadrous reported receiving personal fees from the Centre For Effective Practice outside the submitted work. Dr Desveaux reported receiving personal fees from the Centre for Effective Practice outside the submitted work. Dr Gomes reported receiving grants from the Ontario Ministry of Health outside the submitted work. Dr Taljaard reporting holding a patent unrelated to the submitted work. Dr Bell reported receiving personal fees from the Ontario Ministry of Health during the conduct of the study and outside the submitted work. Dr Ivers reported receiving grants from Government of Ontario Ministry of Health and Long-term Care and the Canadian Institutes of Health Research during the conduct of the study; receiving personal fees from the Centre for Effective Practice outside the submitted work; receiving grants the Canadian Institutes of Health Research and the UK National Institutes of Health Research to support the conduct and evaluation of interventions featuring audit and feedback; being the Women’s College Hospital Chair in Implementation Science; and receiving a Clinician Scholar award from the Department of Family and Community Medicine at the University of Toronto. No other disclosures were reported.

Figures

Figure 1.. Study Flow Diagram for Cluster…
Figure 1.. Study Flow Diagram for Cluster Randomized Trial
Figure 2.. Proportion of Residents Receiving Any…
Figure 2.. Proportion of Residents Receiving Any Antipsychotic Prescription 1 Year Before and After Intervention

References

    1. Hanlon JT, Aspinall SL, Handler SM, et al. . Potentially suboptimal prescribing for older veteran nursing home patients with dementia. Ann Pharmacother. 2015;49(1):20-28. doi:10.1177/1060028014558484
    1. Bonner AF, Field TS, Lemay CA, et al. . Rationales that providers and family members cited for the use of antipsychotic medications in nursing home residents with dementia. J Am Geriatr Soc. 2015;63(2):302-308. doi:10.1111/jgs.13230
    1. Thompson Coon J, Abbott R, Rogers M, et al. . Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review. J Am Med Dir Assoc. 2014;15(10):706-718. doi:10.1016/j.jamda.2014.06.012
    1. Bruser D, McLean J, Bailey A Use of antipsychotics soaring at Ontario nursing homes. Toronto Star Published April 15, 2014. Accessed April 24, 2020.
    1. Ma H, Huang Y, Cong Z, et al. . The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915-937. doi:10.3233/JAD-140579
    1. Rochon PA, Normand SL, Gomes T, et al. . Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168(10):1090-1096. doi:10.1001/archinte.168.10.1090
    1. US Food and Drug Administration Public health advisory: deaths with antipsychotics in elderly with behavioural disturbances. Published April 11, 2005. Accessed April 24, 2020.
    1. Health Canada Health Canada advises consumers about important safety information on atypical antipsychotic drugs and dementia. Accessed April 24, 2020.
    1. Gareri P, De Fazio P, Manfredi VG, De Sarro G. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol. 2014;34(1):109-123. doi:10.1097/JCP.0b013e3182a6096e
    1. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235. doi:10.1056/NEJMoa0806994
    1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943. doi:10.1001/jama.294.15.1934
    1. Tadrous M, Martins D, Herrmann N, et al. Antipsychotics in the elderly: final report: pharmacoepidemiology unit. Ontario Drug Policy Research Network; 2015.
    1. Feng Z, Hirdes JP, Smith TF, et al. . Use of physical restraints and antipsychotic medications in nursing homes: a cross-national study. Int J Geriatr Psychiatry. 2009;24(10):1110-1118. doi:10.1002/gps.2232
    1. Canadian Institute for Health. Information Antipsychotic use in seniors: an analysis focusing on drug claims, 2001 to 2007. Accessed April 24, 2020.
    1. Rochon PA, Stukel TA, Bronskill SE, et al. . Variation in nursing home antipsychotic prescribing rates. Arch Intern Med. 2007;167(7):676-683. doi:10.1001/archinte.167.7.676
    1. Government of Canada Dementia. Updated December 9, 2019. Accessed April 24, 2020.
    1. O’Brien MA, Rogers S, Jamtvedt G, et al. . Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2007;(4):CD000409. doi:10.1002/14651858.CD000409.pub2
    1. Desveaux L, Gomes T, Tadrous M, et al. . Appropriate prescribing in nursing homes demonstration project (APDP) study protocol: pragmatic, cluster-randomized trial and mixed methods process evaluation of an Ontario policy-maker initiative to improve appropriate prescribing of antipsychotics. Implement Sci. 2016;11(1):45. doi:10.1186/s13012-016-0410-x
    1. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147.
    1. Zwarenstein M, Treweek S, Gagnier JJ, et al. ; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group . Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. doi:10.1136/bmj.a2390
    1. Desveaux L, Saragosa M, Rogers J, et al. . Improving the appropriateness of antipsychotic prescribing in nursing homes: a mixed-methods process evaluation of an academic detailing intervention. Implement Sci. 2017;12(1):71. doi:10.1186/s13012-017-0602-z
    1. Desveaux L, Halko R, Marani H, Feldman S, Ivers NM. Importance of team functioning as a target of quality improvement initiatives in nursing homes: a qualitative process evaluation. J Contin Educ Health Prof. 2019;39(1):21-28. doi:10.1097/CEH.0000000000000238
    1. Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group . Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. doi:10.1136/bmj.e5661
    1. Soumerai SB, Avorn J. Principles of educational outreach (‘academic detailing’) to improve clinical decision making. JAMA. 1990;263(4):549-556. doi:10.1001/jama.1990.03440040088034
    1. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ. 2004;328(7453):1415-1416. doi:10.1136/bmj.38068.716262.F7
    1. Juurlink DN, Gomes T, Ko DT, et al. . A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718. doi:10.1503/cmaj.082001
    1. Khan S, Moore JE, Gomes T, et al. . The Ontario Drug Policy Research Network: bridging the gap between research and drug policy. Health Policy. 2014;117(3):392-398. doi:10.1016/j.healthpol.2014.06.007
    1. Fries BE, Simon SE, Morris JN, Flodstrom C, Bookstein FL. Pain in U.S. nursing homes: validating a pain scale for the minimum data set. Gerontologist. 2001;41(2):173-179. doi:10.1093/geront/41.2.173
    1. Koehler M, Rabinowitz T, Hirdes J, et al. . Measuring depression in nursing home residents with the MDS and GDS: an observational psychometric study. BMC Geriatr. 2005;5(1):1. doi:10.1186/1471-2318-5-1
    1. Morris JN, Fries BE, Morris SA. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci. 1999;54(11):M546-M553.
    1. Mor V, Angelelli J, Jones R, Roy J, Moore T, Morris J. Inter-rater reliability of nursing home quality indicators in the U.S. BMC Health Serv Res. 2003;3(1):20. doi:10.1186/1472-6963-3-20
    1. Hirdes JP, Ljunggren G, Morris JN, et al. . Reliability of the interRAI suite of assessment instruments: a 12-country study of an integrated health information system. BMC Health Serv Res. 2008;8(1):277. doi:10.1186/1472-6963-8-277
    1. Burrows AB, Morris JN, Simon SE, Hirdes JP, Phillips C. Development of a Minimum Data Set–based depression rating scale for use in nursing homes. Age Ageing. 2000;29(2):165-172. doi:10.1093/ageing/29.2.165
    1. Ivers NM, Taljaard M, Giannakeas V, Reis C, Williams E, Bronskill S. Public reporting of antipsychotic prescribing in nursing homes: population-based interrupted time series analyses. BMJ Qual Saf. 2019;28(2):121-131. doi:10.1136/bmjqs-2018-007840
    1. Ivers NM, Taljaard M, Giannakeas V, et al. . Effectiveness of confidential reports to physicians on their prescribing of antipsychotic medications in nursing homes. Implementation Sci Commun. 2020;1(1):30. doi:10.1186/s43058-020-00013-9
    1. Ivers N, Jamtvedt G, Flottorp S, et al. . Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2012;(6):CD000259. doi:10.1002/14651858.CD000259.pub3
    1. Iaboni A, Bronskill SE, Reynolds KB, et al. . Changing pattern of sedative use in older adults: a population-based cohort study. Drugs Aging. 2016;33(7):523-533. doi:10.1007/s40266-016-0380-3
    1. Black CD, McCarthy L, Gomes T, Mamdani M, Juurlink D, Tadrous M. Interprovincial variation of psychotropic prescriptions dispensed to older Canadian adults. Can Geriatr J. 2018;21(3):269-273. doi:10.5770/cgj.21.307
    1. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc. 2003;51(9):1305-1317. doi:10.1046/j.1532-5415.2003.51417.x
    1. Riordan DO, Byrne S, Fleming A, Kearney PM, Galvin R, Sinnott C. GPs’ perspectives on prescribing for older people in primary care: a qualitative study. Br J Clin Pharmacol. 2017;83(7):1521-1531. doi:10.1111/bcp.13233
    1. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based “detailing”. N Engl J Med. 1983;308(24):1457-1463. doi:10.1056/NEJM198306163082406

Source: PubMed

3
Se inscrever